Matrix metalloproteinase 3, 8, 9, 12, and 14 (MMP-3/8/9/12/14)

Matrix metalloproteinases (MMPs) 3, 8, 9, 12, and 14 are a group of zinc-dependent endopeptidases that play a fundamental role in the degradation and remodeling of the extracellular matrix (ECM). These enzymes are essential for normal physiological processes such as embryonic development, wound healing, and tissue repair by processing various substrates including collagens, elastins, and cell surface receptors (UniProt, 2024). However, their dysregulation is a hallmark of several pathologies, particularly in cancer where they facilitate tumor invasion, metastasis, and angiogenesis (PubMed, PMID: 28607110). In inflammatory conditions like rheumatoid arthritis and COPD, these specific MMPs contribute to excessive tissue destruction and chronic remodeling (NCBI, 2023). Pharmacological targeting of these enzymes has primarily involved small-molecule inhibitors designed to chelate the catalytic zinc ion. While broad-spectrum inhibitors like Marimastat and Batimastat showed promise in preclinical models, their clinical utility was limited by significant safety concerns, most notably musculoskeletal syndrome (MSS), leading to a shift toward developing more selective inhibitors (StatPearls, 2023).

Other names

Stromelysin-1Neutrophil collagenaseGelatinase BMacrophage metalloelastaseMembrane-type 1 matrix metalloproteinaseMT1-MMPMatrixins

Inhibition of the zinc-dependent catalytic domain to prevent proteolytic cleavage of extracellular matrix substrates and signaling molecules.